journal article·2023-07-11Open access

A Potential Effect of Circadian Rhythm in the Delivery/Therapeutic Performance of Paclitaxel–Dendrimer Nanosystems

Tânia Albuquerque, Ana Raquel Neves, Milan Paul, Swati Biswas, Elena Vuelta, Ignacio García-Tuñón, Manuel Sánchez-Martin, Telma Quintela, Diana Costa

Abstract

The circadian clock controls behavior and physiology. Presently, there is clear evidence of a connection between this timing system and cancer development/progression. Moreover, circadian rhythm consideration in the therapeutic action of anticancer drugs can enhance the effectiveness of cancer therapy. Nanosized drug delivery systems (DDS) have been demonstrated to be suitable engineered platforms for drug targeted/sustained release. The investigation of the chronobiology-nanotechnology relationship, i.e., timing DDS performance according to a patient’s circadian rhythm, may greatly improve cancer clinical outcomes. In the present work, we synthesized nanosystems based on an octa-arginine (R8)-modified poly(amidoamine) dendrimer conjugated with the anticancer drug paclitaxel (PTX), G4-PTX-R8, and its physicochemical properties were revealed to be appropriate for in vitro delivery. The influence of the circadian rhythm on its cellular internalization efficiency and potential therapeutic effect on human cervical cancer cells (HeLa) was studied. Cell-internalized PTX and caspase activity, as a measure of induced apoptosis, were monitored for six time points. Higher levels of PTX and caspase-3/9 were detected at T8, suggesting that the internalization of G4-PTX-R8 into HeLa cells and apoptosis are time-specific/-regulated phenomena. For a deeper understanding, the clock protein Bmal1—the main regulator of rhythmic activity, was silenced by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Bmal1 silencing was revealed to have an impact on both PTX release and caspase activity, evidencing a potential role for circadian rhythm on drug delivery/therapeutic effect mediated by G4-PTX-R8.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Dendrimers and Hyperbranched Polymers · Gold and Silver Nanoparticles Synthesis and Applications · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CICS-UBI—Health Sciences Research Centre, Universidade da Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal

Department of Pharmacy, Nanomedicine Research Laboratory, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad 500078, Telangana, India

Servicio de Transgénesis, Nucleus, Universidad de Salamanca, 37008 Salamanca, Spain

IBSAL, Instituto de Investigación Biomédica de Salamanca, 37007 Salamanca, Spain

Departamento de Medicina, Universidad de Salamanca, 37008 Salamanca, Spain

Unidad de Diagnóstico Molecular y Celular del Cáncer, Instituto Biología Molecular y Celular del Cáncer (USAL/CSIC), 37007 Salamanca, Spain

UDI-IPG-Unidade de Investigação para o Desenvolvimento do Interior, Instituto Politécnico da Guarda, 6300-559 Guarda, Portugal

Funding

Fundação para a Ciência e a Tecnologia (FCT) · European Social Fund via Programa Operacional Regional Centro · Indian Council of Medical Research (ICMR) · national funds through the Portuguese FCT/MCTES

References (68)

Show source-provided references
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21492 ↗
2. Pfeffer, C.M., and Singh, A.T.K. (2018). Apoptosis: A Target for Anticancer Therapy. Int. J. Mol. Sci., 19.10.3390/ijms19020448 ↗
3. Nanoparticles for Cancer Therapy: Current Progress and Challenges10.1186/s11671-021-03628-6 ↗
4. Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology10.1177/1559325820936161 ↗
5. Application of Nanotechnology in Cancer Diagnosis and Therapy—A Mini-Review10.7150/ijms.49801 ↗
6. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives10.2147/IJN.S289443 ↗
7. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
8. Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy10.2147/IJN.S274289 ↗
9. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery10.1016/j.eurpolymj.2021.110683 ↗
10. Nimesh, S. (2013). Gene Therapy, Woodhead Publishing.10.1533/9781908818645 ↗
11. Andronescu, E., and Grumezescu, A.M. (2017). Nanostructures for Oral Medicine, Elsevier.
12. Octa-arginine modified poly(amidoamine) dendrimers for improved delivery and cytotoxic effect of paclitaxel in cancer10.1080/21691401.2018.1470527 ↗
13. Effect of methotrexate conjugated PAMAM dendrimers on the viability of MES-SA uterine cancer cells10.4103/0975-7406.142963 ↗
14. Zhang, M., Zhu, J., Zheng, Y., Guo, R., Wang, S., Mignani, S., Caminade, A.M., Majoral, J.P., and Shi, X. (2018). Doxorubicin-Conjugated PAMAM Dendrimers for pH-Responsive Drug Release and Folic Acid-Targeted Cancer Therapy. Pharmaceutics, 10.10.3390/pharmaceutics10030162 ↗
15. Docetaxel-loaded PAMAM-based poly (γ-benzyl-l-glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles in human breast cancer and human cervical cancer therapy
16. Boisguérin, P., Konate, K., Josse, E., Vivès, E., and Deshayes, S. (2021). Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery. Biomedicines, 9.10.3390/biomedicines9050583 ↗
17. Neves, A.R., Albuquerque, T., Faria, R., Gonçalves, A.M., Santos, C., Vivès, E., Boisguérin, P., Passarinha, L.A., Sousa, Â., and Costa, D. (2022). Development of WRAP5 Peptide Complexes for Targeted Drug/Gene Co-Delivery toward Glioblastoma Therapy. Pharmaceutics, 14.10.3390/pharmaceutics14102213 ↗
18. Cell-Penetrating Peptide and α-Tocopherol-Conjugated Poly(amidoamine) Dendrimers for Improved Delivery and Anticancer Activity of Loaded Paclitaxel10.1021/acsabm.0c00179 ↗
19. Sheldon, S.H., Ferber, R., and Kryger, M.H. (2005). Principles and Practice of Pediatric Sleep Medicine, W.B. Saunders.10.1016/B978-0-7216-9458-0.50006-4 ↗
20. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial10.1002/cam4.3056 ↗
21. A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy10.1080/07420528.2017.1397684 ↗
22. Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis10.1016/j.ccell.2016.10.007 ↗
23. Concurrent Disruption of the Ras/MAPK and NF-κB Pathways Induces Circadian Deregulation and Hepatocarcinogenesis10.1158/1541-7786.MCR-21-0479 ↗
24. Co-existing feedback loops generate tissue-specific circadian rhythms10.26508/lsa.201800078 ↗
25. Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma10.1177/0748730417696788 ↗
26. Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling10.1158/1535-7163.MCT-15-0129 ↗
27. Albuquerque, T., Neves, A.R., Quintela, T., and Costa, D. (2022). The Influence of Circadian Rhythm on Cancer Cells Targeting and Transfection Efficiency of a Polycation-Drug/Gene Delivery Vector. Polymers, 14.10.3390/polym14040681 ↗
28. PAMAM Dendrimer-Based Multifunctional Conjugate for Cancer Therapy: Synthesis, Characterization, and Functionality10.1021/bm0506142 ↗
29. Dendritic polyglycerol sulfate as a novel platform for paclitaxel delivery: Pitfalls of ester linkage10.1039/C4NR04428B ↗
30. Hypoxia alleviating platinum(IV)/chlorin e6-based combination chemotherapeutic-photodynamic nanomedicine for oropharyngeal carcinoma10.1016/j.jphotobiol.2022.112627 ↗
31. Dual peptide conjugation strategy for improved cellular uptake and mitochondria targeting10.1021/bc500408p ↗
32. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer
33. Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma10.1016/j.ijpharm.2022.121479 ↗
34. Neves, A.R., Albuquerque, T., Faria, R., Paul, M., Biswas, S., Sousa, Â., and Costa, D. (2021). Development of Tailor-Made Dendrimer Ternary Complexes for Drug/Gene Co-Delivery in Cancer. Pharmaceutics, 13.10.3390/pharmaceutics13081256 ↗
35. Ferreira, M., Gomes, D., Neto, M., Passarinha, L.A., Costa, D., and Sousa, Â. (2023). Development and Characterization of Quercetin-Loaded Delivery Systems for Increasing Its Bioavailability in Cervical Cancer Cells. Pharmaceutics, 15.10.3390/pharmaceutics15030936 ↗
36. Vuelta, E., Ordonez, J., Alonso Pérez, V., Mendez, L., Hernández-Carabias, P., Saldana, R., Sevilla, J., Sebastian, E., Muntion, S., and Sanchez-Guijo, F. (2020). CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis. bioRxiv, 103–112.10.1101/2020.08.05.237610 ↗
37. Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment10.1016/j.apsb.2020.07.023 ↗
38. Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel10.21873/anticanres.11289 ↗
39. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis10.2147/IJN.S290731 ↗
40. Nawara, H.M., Afify, S.M., Hassan, G., Zahra, M.H., Seno, A., and Seno, M. (2021). Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. Biomedicines, 9.10.3390/biomedicines9050500 ↗
41. Mudalige, T., Qu, H., Haute, D., Ansar, S., Paredes, A., and Ingle, T. (2019). Nanomaterials for Food Applications, Elsevier.
42. Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells10.1016/j.ijpharm.2021.120217 ↗
43. Influence of chronobiology on the nanoparticle-mediated drug uptake into the brain10.3390/pharmaceutics7010003 ↗
44. Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation10.1016/j.ijpharm.2016.11.047 ↗
45. García-Tuñón, I., Vuelta, E., Pérez-Ramos, S., Hernández, J., Méndez, L., Herrero, M., and Sanchez-Martin, M. (2018). Modulating Gene Expression-Abridging the RNAi and CRISPR-Cas9 Technologies, Intechopen.
46. The times they’re a-changing: Effects of circadian desynchronization on physiology and disease
47. The Circadian Clock Gene Bmal1 Controls Intestinal Exporter MRP2 and Drug Disposition10.7150/thno.33395 ↗
48. CLOCK and BMAL1 regulate MyoD and are necessary for maintenance of skeletal muscle phenotype and function10.1073/pnas.1014523107 ↗
49. Streamlined procedure for gene knockouts using all-in-one adenoviral CRISPR-Cas910.1038/s41598-018-36736-y ↗
50. PAMAM dendrimer—Cell membrane interactions10.1016/j.cis.2018.06.005 ↗
51. Cell Death Signaling10.1101/cshperspect.a006080 ↗
52. Caspase—9: Structure, mechanisms and clinical application10.18632/oncotarget.15098 ↗
53. Lossi, L., Castagna, C., and Merighi, A. (2018). Caspase-3 Mediated Cell Death in the Normal Development of the Mammalian Cerebellum. Int. J. Mol. Sci., 19.10.20944/preprints201811.0592.v1 ↗
54. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy10.1038/sj.onc.1209608 ↗
55. Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9 activation in NB4 human leukaemia cells is not modulated by ERK inhibition
56. Miller, A.V., Hicks, M.A., Nakajima, W., Richardson, A.C., Windle, J.J., and Harada, H. (2013). Paclitaxel-Induced Apoptosis Is BAK-Dependent, but BAX and BIM-Independent in Breast Tumor. PLoS ONE, 8.10.1371/journal.pone.0060685 ↗
57. A novel synergistic anticancer effect of fungal cholestanol glucoside and paclitaxel: Apoptosis induced by an intrinsic pathway through ROS generation in cervical cancer cell line (HeLa)10.1016/j.tiv.2021.105079 ↗
58. Mechanisms of cancer cell death induction by paclitaxel: An updated review10.1007/s10495-022-01750-z ↗
59. Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways10.1016/j.csbj.2021.05.011 ↗
60. Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle10.1126/sciadv.abd2645 ↗
61. The Circadian Gene Clock Plays an Important Role in Cell Apoptosis and the DNA Damage Response In Vitro10.1177/1533034615585433 ↗
62. Cisplatin’s dual-effect on the circadian clock triggers proliferation and apoptosis10.1016/j.nbscr.2020.100054 ↗
63. Gwon, D.H., Lee, W.Y., Shin, N., Kim, S.I., Jeong, K., Lee, W.H., Kim, D.W., Hong, J., and Lee, S.Y. (2020). BMAL1 Suppresses Proliferation, Migration, and Invasion of U87MG Cells by Downregulating Cyclin B1, Phospho-AKT, and Metalloproteinase-9. Int. J. Mol. Sci., 21.10.3390/ijms21072352 ↗
64. Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma10.1158/0008-5472.CAN-16-1322 ↗
65. Circadian clock gene BMAL1 inhibits the proliferation and tumor-formation ability of nasopharyngeal carcinoma cells and increases the sensitivity of radiotherapy10.1080/07420528.2022.2105708 ↗
66. The circadian rhythm controls telomeres and telomerase activity10.1016/j.bbrc.2014.07.138 ↗
67. Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle10.1073/pnas.2214829120 ↗
68. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma10.1002/ijc.27598 ↗